Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men

INTRODUCTION: Oral HIV Pre‐Exposure Prophylaxis (PrEP) with tenofovir (TFV) disoproxil fumarate (TDF)/emtricitabine (FTC) is highly effective. Transgender women (TGW) have increased HIV risk, but have been underrepresented in trials. For TGW on oestrogens for gender‐affirming hormone treatment (GAHT...

Descripción completa

Detalles Bibliográficos
Autores principales: Shieh, Eugenie, Marzinke, Mark A, Fuchs, Edward J, Hamlin, Allyson, Bakshi, Rahul, Aung, Wutyi, Breakey, Jennifer, Poteat, Tonia, Brown, Todd, Bumpus, Namandjé N, Hendrix, Craig W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832671/
https://www.ncbi.nlm.nih.gov/pubmed/31692269
http://dx.doi.org/10.1002/jia2.25405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832671/
https://www.ncbi.nlm.nih.gov/pubmed/31692269
http://dx.doi.org/10.1002/jia2.25405

Ejemplares similares